207 results on '"Kluger H"'
Search Results
2. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
3. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma
4. 1582P Real-world management of immune-related adverse events in the community setting
5. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
6. 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
7. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma
8. P14.05 Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors
9. Supplement to: Nivolumab plus ipilimumab in advanced melanoma.
10. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality
11. 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
12. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer
13. 187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours
14. Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
15. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
16. Somatic mutation status of melanomas and effect on clinical outcome in patients on ecog 2603
17. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer
18. HSP90 as a marker of progression in melanoma
19. Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
20. LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma
21. Alpha B crystallin, a novel marker for breast cancer metastasis
22. 3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy
23. The Influence of Oxindanac on Kallikrein Metabolism
24. P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
25. PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
26. Abstracts from the 4th ImmunoTherapy of Cancer Conference
27. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
28. 1375TiP - Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
29. Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients
30. 22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
31. HuR binds to a novel 99nt non AU-rich element in 3'UTR c-fms RNA, regulating its expression, and is a poor prognostic factor in breast cancer
32. 1212TiP - PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
33. HuR regulates c-fms proto-oncogene expression by binding to a 99nt non AU-rich region in 3'UTR c-fms RNA and is an independent poor prognostic factor in breast cancer
34. On the Archetype as a Prognostic Factor
35. BM-10 * SYSTEMIC TREATMENT AND RADIATION NECROSIS FOLLOWING GKSRS IN THE TREATMENT OF BRAIN METASTASES
36. Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel)
37. Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial
38. Immunomodulatory Activity of Nivolumab in Previously Treated and Untreated Metastatic Renal Cell Carcinoma (Mrcc): Biomarker-Based Results from a Randomized Clinical Trial
39. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
40. 1055O - Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients
41. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma
42. IMMUNOTHERAPY
43. C-met as a therapeutic target using ARQ 197 in renal cell carcinoma.
44. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.
45. A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies
46. Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma
47. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma
48. A phase II trial of dasatinib in advanced melanoma
49. Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancer
50. A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.